The Flow Cytometry and Cellular Imaging Core Facility (FCCICF) provides cellular analysis to investigatorswith peer-reviewed grants. The FCCICF has two sites, on the north campus and on the recently-openedsouth campus. It occupies 1900 sq. ft. and is directed by Dr. Michael Andreeff. The FCCICF develops andprovides techniques for single-cell analysis. Cell phenotyping, proliferation, signaling and apoptosis assayshave been established and modified for multiparametric analysis. Immunophenotypic analysis was combinedwith assays of intracellular proteins related to apoptosis (Bcl-2, Bcl-XL, BAG-1, p53, Rb, caspase activation,mitochondria! membrane potential and Fas), cell signaling (MARK), proliferation (Ki67, cyclins, BrDU, PCNA,DNA) and cell division history (CFSE). Quantitation of cellular antigens allows determination of the antibodybindingcapacity per cell. Rare events and progenitor/stem cell subpopulations can be detected and isolatedby three-laser excitation/eight-parameter fluorescence-activated cell sorting (FACS) for subsequent analysisby molecular cytogenetic and other molecular techniques including quantitation of intracellular PKCoc, Bax,Bcl-2, ERK, pERK, XIAP by laser scanning cytometry. FISH has been combined with apoptosis assays todiscriminate apoptosis in normal and malignant cells. The number, phenotype and proliferation of minimalresidual disease cells can be determined at levels of one malignant in 30,000 normal cells. Methods fordetection of transgene expression in cells are in place using p-galactosidase (p-gal), nerve growth factorreceptor (NGF-R), and green fluorescent protein (EGFP). Acquisition of 3 new FACS Aria cell sorters and afour-laser flow cytometer (B&D LSRII) has upgraded the facility to provide state-of-the-art isolation andanalysis. Laser confocal microscopy has been used extensively and was upgraded by acquisition of anOlympus FV-500 multi-user instrument and a DSU spinning disc confocal system. High-impact studies incancer prevention, growth factor signaling in breast cancer, apoptosis regulation in leukemias and multisteptumorigenesis all utilized confocal microscopy. The FCCICF now utilizes 17 major instrument systems. TheCore supports numerous R01, P01, R21, and SPORE grants. Since the previous review, the number ofusers has increased 145% (169 investigators with peer-reviewed grants from 19 different programs). 67% ofusers have peer-reviewed funding. During the previous funding period, 11,668 hours of service wasprovided. Use has tripled to greater than 7,000 hours estimated for 2007. Future plans are focused on thecontinued development and application of cutting-edge technologies in cell analysis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-33
Application #
7695941
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-08-28
Project End
2013-06-30
Budget Start
2008-08-28
Budget End
2009-06-30
Support Year
33
Fiscal Year
2008
Total Cost
$359,564
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :
Patel, V K; Lamothe, B; Ayres, M L et al. (2018) Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia 32:920-930
Ravandi, Farhad; Ritchie, Ellen K; Sayar, Hamid et al. (2018) Phase 3 results for vosaroxin/cytarabine in the subset of patients ?60 years old with refractory/early relapsed acute myeloid leukemia. Haematologica 103:e514-e518
Assi, Rita; Kantarjian, Hagop M; Kadia, Tapan M et al. (2018) Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Cancer 124:2758-2765
Yam, Clinton; Murthy, Rashmi K; Valero, Vicente et al. (2018) A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. Invest New Drugs 36:299-306
Lacourt, Tamara E; Vichaya, Elisabeth G; Escalante, Carmen et al. (2018) An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology 96:109-117
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Neelapu, Sattva S; Tummala, Sudhakar; Kebriaei, Partow et al. (2018) Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'. Nat Rev Clin Oncol 15:218
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J et al. (2018) Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer 118:1425-1433

Showing the most recent 10 out of 12418 publications